Advertisement

World Journal of Surgery

, Volume 41, Issue 6, pp 1558–1565 | Cite as

Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer

  • Yuta Ibuki
  • Yoichi HamaiEmail author
  • Jun Hihara
  • Manabu Emi
  • Junya Taomoto
  • Takaoki Furukawa
  • Ichiko Yamakita
  • Tomoaki Kurokawa
  • Morihito Okada
Original Scientific Report

Abstract

Background

Elevated preoperative serum C-reactive protein (CRP) levels are reportedly associated with a poor prognosis for patients with various types of malignant tumors. However, the impact of postoperative CRP levels on the prognosis of patients with esophageal cancer remains unknown. The present study aims to clarify the prognostic significance of postoperative CRP levels on the survival of patients with esophageal cancer.

Methods

We reviewed the records of consecutive 202 patients with thoracic esophageal squamous cell carcinoma who underwent transthoracic esophagectomy. We measured serum CRP levels on postoperative days (PODs) 1, 2, 3, 5 and 7 and evaluated the relationships between postoperative CRP levels and survival.

Results

The findings of Cox regression analyses suggested that elevated CRP levels on POD 3, 5 and 7 were associated with poor recurrence-free survival (RFS). We divided CRP levels on POD 7 into three tertiles and found that RFS could be clearly stratified, being the poorest (p < 0.001) in the highest tertile (high CRP). The trend was similar even in patients with or without infectious complications and with or without advanced pathological stage. Multivariate analysis showed that pathologically advanced stage (Hazard ratio [HR], 5.14; 95% confidence interval [CI] 2.67–9.87; p < 0.001) and high CRP (HR, 2.27; 95% CI 1.3–3.96; p = 0.004) were independent predictors of RFS.

Conclusion

Postoperative CRP levels could predict the prognosis of patients with esophageal cancer. We propose that the clinical course of postoperative CRP level should be carefully monitored as a predictor of survival.

Keywords

Esophageal Cancer Esophageal Squamous Cell Carcinoma Infectious Complication Sivelestat Thoracic Esophageal Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Shimada H, Nabeya Y, Okazumi S et al (2003) Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 133:486–494CrossRefPubMedGoogle Scholar
  2. 2.
    Munck-Wikland E, Kuylenstierna R, Wahren B et al (1988) Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 62:2281–2286CrossRefPubMedGoogle Scholar
  3. 3.
    Brockmann JG, St Nottberg H, Glodny B et al (2000) CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6:4249–4252PubMedGoogle Scholar
  4. 4.
    Alifano M, Falcoz PE, Seegers V et al (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142:1161–1167CrossRefPubMedGoogle Scholar
  5. 5.
    Baba H, Kuwabara K, Ishiguro T et al (2013) C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients. Anticancer Res 33:5591–5595PubMedGoogle Scholar
  6. 6.
    Jang JW, Oh BS, Kwon JH et al (2012) Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine 60:686–693CrossRefPubMedGoogle Scholar
  7. 7.
    Szkandera J, Stotz M, Absenger G et al (2014) Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 110:183–188CrossRefPubMedGoogle Scholar
  8. 8.
    Hu Q, Gou Y, Sun C et al (2014) The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 32(50):e1–e8Google Scholar
  9. 9.
    Nozoe T, Saeki H, Sugimachi K (2001) Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 182:197–201CrossRefPubMedGoogle Scholar
  10. 10.
    Ikeda M, Natsugoe S, Ueno S et al (2003) Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 238:197–202PubMedPubMedCentralGoogle Scholar
  11. 11.
    Shimada H, Nabeya Y, Okazumi S et al (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83:248–252CrossRefPubMedGoogle Scholar
  12. 12.
    Gockel I, Dirksen K, Messow CM et al (2006) Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 12:3746–3750CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang CY, Hsieh MJ, Chiu YC et al (2009) Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 92:270–275CrossRefPubMedGoogle Scholar
  14. 14.
    Guillem P, Triboulet JP (2005) Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus 18:146–150CrossRefPubMedGoogle Scholar
  15. 15.
    Zingg U, Forberger J, Rajcic B et al (2010) Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 14:462–469CrossRefPubMedGoogle Scholar
  16. 16.
    Ben-Baruch A (2006) Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16:38–52CrossRefPubMedGoogle Scholar
  17. 17.
    Keibel A, Singh V, Sharma MC (2009) Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 15:1949–1955CrossRefPubMedGoogle Scholar
  18. 18.
    Hirai T, Yoshimoto A, Iwata T et al (1997) Enhancing effect of thoraco-laparotomy on liver metastasis and the role played by active oxygens in its mechanism. Surg Today 27:1040–1045CrossRefPubMedGoogle Scholar
  19. 19.
    Sobin LH, Gospodarowicz MK, Wittekind CH (2009) TNM classification of malignant tumours, 7th edn. Wiley, HobokenGoogle Scholar
  20. 20.
    Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Aarden LA, De Groot ER, Schaap OL et al (1987) Production of hybridoma growth factor by human monocytes. Eur J Immunol 17:1411–1416CrossRefPubMedGoogle Scholar
  22. 22.
    Sironi M, Breviario F, Proserpio P et al (1989) IL-1 stimulates IL-6 production in endothelial cells. J Immunol 142:549–553PubMedGoogle Scholar
  23. 23.
    Shiba H, Furukawa K, Fujiwara Y et al (2013) Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma. Anticancer Res 33:705–709PubMedGoogle Scholar
  24. 24.
    Johnson TV, Abbasi A, Owen-Smith A et al (2010) Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 76(766):e1–e5Google Scholar
  25. 25.
    Ito K, Yoshii H, Sato A et al (2011) Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol 186:430–435CrossRefPubMedGoogle Scholar
  26. 26.
    Chen MF, Chen PT, Lu MS et al (2013) IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer. doi: 10.1186/1476-4598-12-26 Google Scholar
  27. 27.
    Nozoe T, Korenaga D, Futatsugi M et al (2003) Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus—significance as a tumor marker. Cancer Lett 192:89–95CrossRefPubMedGoogle Scholar
  28. 28.
    Nakatsu T, Motoyama S, Maruyama K et al (2012) Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today 42:652–658CrossRefPubMedGoogle Scholar
  29. 29.
    Roth-Isigkeit A, Hasselbach L, Ocklitz E et al (2001) Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass. Clin Exp Immunol 125:80–88CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Misoph M, Babin-Ebell J (1997) Interindividual variations in cytokine levels following cardiopulmonary bypass. Heart Vessels 12:119–127CrossRefPubMedGoogle Scholar
  31. 31.
    Lee Y, Park US, Choi I et al (1998) Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res 4:1711–1717PubMedGoogle Scholar
  32. 32.
    Lee YH, Nair S, Rousseau E et al (2005) Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 48:1776–1783CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nagasaki T, Hara M, Nakanishi H et al (2014) Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 110:469–478CrossRefPubMedGoogle Scholar
  34. 34.
    Gado K, Domjan G, Hegyesi H et al (2000) Role of interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 24:195–209CrossRefPubMedGoogle Scholar
  35. 35.
    Black S, Kushner I, Samols D (2004) C-reactive protein: minireview. J Biol Chem 279:48487–48490CrossRefPubMedGoogle Scholar
  36. 36.
    Sato N, Koeda K, Ikeda K et al (2002) Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg 236:184–190CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kawahara Y, Ninomiya I, Fujimura T et al (2010) Prospective randomized controlled study on the effects of perioperative administration of a neutrophil elastase inhibitor to patients undergoing video-assisted thoracoscopic surgery for thoracic esophageal cancer. Dis Esophagus 23:329–339CrossRefPubMedGoogle Scholar
  38. 38.
    Wada Y, Yoshida K, Hihara J et al (2006) Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. Cancer Sci 97:1037–1043CrossRefPubMedGoogle Scholar
  39. 39.
    Kubota H, Matsumoto H, Higashida M et al (2013) Eicosapentaenoic acid modifies cytokine activity and inhibits cell proliferation in an oesophageal cancer cell line. Anticancer Res 33:4319–4324PubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2017

Authors and Affiliations

  • Yuta Ibuki
    • 1
  • Yoichi Hamai
    • 1
    Email author
  • Jun Hihara
    • 1
  • Manabu Emi
    • 1
  • Junya Taomoto
    • 1
  • Takaoki Furukawa
    • 1
  • Ichiko Yamakita
    • 1
  • Tomoaki Kurokawa
    • 1
  • Morihito Okada
    • 1
  1. 1.Department of Surgical Oncology, Research Institute for Radiation Biology and MedicineHiroshima UniversityHiroshimaJapan

Personalised recommendations